Plain-English translation of NCT05727722 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-stage trial is testing micro-encapsulated hepatocytes — liver cells that are wrapped in a protective coating — transplanted directly into the abdomen to treat people with severe liver failure. Researchers want to find the safest and most effective dose of these cells. Participants will receive one transplant and be monitored closely for 60 days to see if the treatment is safe and whether it helps their liver function improve.
When the liver fails and standard treatments don't work, patients have very few options. This treatment aims to give the liver cells a chance to help the body's own liver recover, offering hope to people in critical condition who might otherwise need a full liver transplant or face life-threatening complications.
You likely qualify if…
You likely don't qualify if…
If you enroll, you'll receive one infusion of the specially wrapped liver cells directly into your abdomen — a one-time procedure. After that, you'll have follow-up visits at days 1, 3, 7, 14, 28, and 60 to have blood tests and check-ups to monitor your safety and how well the treatment is working. You can continue receiving other standard liver treatments, including a traditional liver transplant if needed, while you're in the study.
AI-generated summary from trial data · Jul 11, 2026 · Not medical advice
China